This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 consolidated revenue up 31.4%, profit after tax up 55.8%
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations rose 31.4% year on year to INR 655 crore and profit after tax rose 55.8% to INR 57 crore. EBITDA was INR 186 crore, with margin down to 27.9% from 28.4%. For consolidated H1 FY27, revenue was INR 1,269 crore and PAT INR 112 crore. Comparatives were restated for the Dr Agarwal's Eye Hospital merger; auditor review was unmodified.
Strong revenue and profit growth should support sentiment, but the slight EBITDA margin decline and merger-related restatement warrant monitoring.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹655.5 Cr | ₹498.7 Cr | +31.4% |
| Operating profit | ₹70.14 Cr | ₹45.73 Cr | +53.4% |
| Profit after tax | ₹56.85 Cr | ₹36.49 Cr | +55.8% |
| EBITDA margin | 26.8% | 27.3% | −0.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.